BioSpace News Archive

Tulane researchers James McLachlan and Lisa Morici explain how nanoparticles shed from bacteria can be used in future vaccines to illicit a more potent immune response than existing technologies. The project aims to design a more effective vaccine against pertussis.

SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 30th September 2018. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 14th Nov’ 2018 at Hyderabad.

Four ongoing clinical trial programs

Commercial Operations Leaders Meet to Sort Fact from Fiction

New Regenstrief and IU methodology identifies, swiftly implements evidence-based solutions

How can a doctor predict the treatment outcome of an individual patient? Traditionally, the effectiveness of medical treatments is studied by randomised trials where patients are randomly divided into two groups: one of the groups is given treatment, and the other a placebo.

Approval is based on Phase 3 SPARTAN clinical study data which showed apalutamide decreased the risk of distant metastasis or death by 72 percent and improved median metastasis-free survival by more than two years

AbbVie could be eyeing another potential billion dollars of annual revenue following the accelerated approval of Venclexta for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older or who cannot tolerate intensive chemotherapy.

He Jiankui, a researcher in Shenzhen, China, claims he utilized CRISPR-Cas9 gene editing to alter the DNA of embryos for seven couples. The gene editing was done to give the children protection from HIV, which each of the fathers carried.

Shares of Boston-based Zafgen, Inc. plunged more than 32 percent in pre-market trading after the company announced the U.S. Food and Drug Administration has slapped a clinical hold on its plans to launch a clinical trial in the United States for an experimental diabetes medicine due to safety concerns.